Oncolytics (ONCY) Biotech announced the appointment of Jared Kelly as CEO and a member of its Board of Directors. Kelly is a successful biotech executive who has proven expertise in transformative deals and corporate strategy. Most recently, he played a central role in orchestrating the sale of Ambrx Biopharma to Johnson & Johnson for $2B. Prior to Ambrx, he advised multiple leading-edge biotech companies on M&A and licensing transactions at highly respected law firms, including Lowenstein Sandler LLP and Kirkland & Ellis LLP. He is a JD and LLM graduate of Georgetown Law.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONCY:
- Oncolytics Biotech Unveils Promising Pelareorep Data at ASCO 2025
- Oncolytics presents new data from Phase I/II GOBLET clinical trial
- Promising Clinical Developments and Strategic Advancements Justify Buy Rating for Oncolytics Biotech
- Oncolytics downgraded to Hold from Buy at JonesResearch
- Oncolytics Biotech’s Strategic Advances in Oncology: Promising Developments in Breast and Pancreatic Cancer Research